These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
762 related items for PubMed ID: 15509615
21. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC. J Antimicrob Chemother; 2004 Apr; 53(4):604-8. PubMed ID: 14973153 [Abstract] [Full Text] [Related]
22. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Tan TY, Ng SY. Clin Microbiol Infect; 2007 May; 13(5):541-4. PubMed ID: 17371537 [Abstract] [Full Text] [Related]
23. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. MacKenzie FM, Smith SV, Milne KE, Griffiths K, Legge J, Gould IM. J Cyst Fibros; 2004 Aug; 3(3):151-7. PubMed ID: 15463901 [Abstract] [Full Text] [Related]
24. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. Mathy V, Grohs P, Compain F. J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231 [Abstract] [Full Text] [Related]
25. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). Gales AC, Jones RN, Sader HS. J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434 [Abstract] [Full Text] [Related]
26. [Evaluation of a new E-test method for antimicrobial sensitivity testing of Pseudomonas aeruginosa isolates from cystic fibrosis]. Zebouh M, Thomas C, Honderlick P, Lemee L, Segonds C, Wallet F, Husson MO. Pathol Biol (Paris); 2005 Sep; 53(8-9):490-4. PubMed ID: 16087300 [Abstract] [Full Text] [Related]
27. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp]. Vay CA, Almuzara MN, Rodríguez CH, Pugliese ML, Lorenzo Barba F, Mattera JC, Famiglietti AM. Rev Argent Microbiol; 2005 Sep; 37(1):34-45. PubMed ID: 15991478 [Abstract] [Full Text] [Related]
28. Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. Goncalves-Vidigal P, Grosse-Onnebrink J, Mellies U, Buer J, Rath PM, Steinmann J. J Cyst Fibros; 2011 Dec; 10(6):422-7. PubMed ID: 21763218 [Abstract] [Full Text] [Related]
29. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V. J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [Abstract] [Full Text] [Related]
30. Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum. Kolpen M, Kragh KN, Bjarnsholt T, Line L, Hansen CR, Dalbøge CS, Hansen N, Kühl M, Høiby N, Jensen PØ. Int J Med Microbiol; 2015 Jan; 305(1):1-10. PubMed ID: 25441256 [Abstract] [Full Text] [Related]
31. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821 [Abstract] [Full Text] [Related]
32. [Comparison between agar dilution and three other methods for determining the susceptibility of 228 clinical isolates of non-fermenting gram-negative rods]. Gómez-Garcés JL, Aracil B, Gil Y. Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):331-7. PubMed ID: 19406523 [Abstract] [Full Text] [Related]
33. Comparative activity of antimicrobials against Pseudomonas aeruginosa, Achromobacter xylosoxidans and Stenotrophomonas maltophilia keratitis isolates. Spierer O, Miller D, O'Brien TP. Br J Ophthalmol; 2018 May; 102(5):708-712. PubMed ID: 29459431 [Abstract] [Full Text] [Related]
35. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R, BSAC Working Parties on Resistance Surveillance. J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii55-63. PubMed ID: 18819980 [Abstract] [Full Text] [Related]
36. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms. Bosso JA, Mauldin PD, Steed LL. Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687 [Abstract] [Full Text] [Related]
37. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T. J Antimicrob Chemother; 2013 Mar; 68(3):636-9. PubMed ID: 23134658 [Abstract] [Full Text] [Related]
38. Emerging and unusual gram-negative infections in cystic fibrosis. Davies JC, Rubin BK. Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501 [Abstract] [Full Text] [Related]
39. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. Jones RN, Anderegg TR, Swenson JM, Quality Control Working Group. J Clin Microbiol; 2005 Feb; 43(2):925-7. PubMed ID: 15695708 [Abstract] [Full Text] [Related]
40. Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France. Biswas S, Dubus JC, Reynaud-Gaubert M, Stremler N, Rolain JM. Eur J Clin Microbiol Infect Dis; 2013 Nov; 32(11):1461-4. PubMed ID: 23719852 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]